JPMorgan lowered the firm’s price target on Teradyne (TER) to $120 from $145 and keeps an Overweight rating on the shares. While the company said macro factors are leading to push outs and reviews of capital plans, the revision to the guidance just over a month after providing a 2025 outlook, which tracked below investor expectations to start with, will likely increase concerns on Teradyne’s ability to forecast its business, the analyst tells investors in a research note. However, the firm believes consensus expectations are now more conservative, leaving limited share downside from current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TER:
- Cathie Wood’s ARK Investment bought 162K shares of Teradyne today
- Teradyne’s Promising Growth Prospects and Strategic Initiatives Justify Buy Rating
- Teradyne sees Q2 revenue ‘flat to down 10%’ vs. Q1
- Teradyne down 16% at $87.80 after Analyst Day targets for Q2, FY25
- Teradyne to acquire Quantifi Photonics, terms not disclosed
Questions or Comments about the article? Write to editor@tipranks.com